Innovations for Next-Generation Antibody-Drug Conjugates
Overview of attention for book
Table of Contents
-
Altmetric BadgeBook Overview
-
Altmetric BadgeChapter 1 Introduction: Motivations for Next-Generation ADCs
-
Altmetric BadgeChapter 2 Combining ADCs with Immuno-Oncology Agents
-
Altmetric BadgeChapter 3 Improving the Safety Profile of ADCs
-
Altmetric BadgeChapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development
-
Altmetric BadgeChapter 5 Regulatory Considerations and Companion Diagnostics
-
Altmetric BadgeChapter 6 Outlook on Next Generation Technologies and Strategy Considerations for ADC Process Development and Manufacturing
-
Altmetric BadgeChapter 7 HER2-Targeted ADCs: At the Forefront of ADC Technology Development
-
Altmetric BadgeChapter 8 Next Generation Payloads for ADCs
-
Altmetric BadgeChapter 9 Delivering More Payload (High DAR ADCs)
-
Altmetric BadgeChapter 10 Site-Specific Antibody-Drug Conjugates
-
Altmetric BadgeChapter 11 Bispecific and Biparatopic Antibody Drug Conjugates
-
Altmetric BadgeChapter 12 Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates
-
Altmetric BadgeChapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment
-
Altmetric BadgeChapter 14 Next Horizons: ADCs Beyond Oncology